Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel – ABHH monoclonal gammopathies committe

Hungria, Vania T.M.; Garnica, Márcia; Crusoé, Edvan; Filho, Roberto Jose Pessoa de Magalhaes; Martínez, Gracia; Bittencourt, Rosane; Farias, Danielle Leão Cordeiro de; Braga, Walter Moisés Tobias; Neto, Jorge Megid; Ribeiro, Gustavo Meirelles; Maiolino, Ângelo

doi:10.1016/j.htct.2020.05.001

Cited by 12 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8,11,12 To date there is very limited information regarding characteristics and outcomes of MM patients with COVID-19, with only a single case report 13 and a small UK series of 75 heterogeneous patients that did not report a non-MM reference group of patients with COVID-19. 14 Several international and national guidelines have been reported, [15][16][17][18][19] providing guidance to physicians on the management of patients with MM during the COVID-19 pandemic; however, these recommendations are based on consensus and general disease concepts, and lack specific data derived from infected patients. To our knowledge this is the first large case-series study to describe comprehensively the clinical characteristics of COVID-19 in hospitalized MM patients, compare outcomes with a non-cancer cohort of COVID-19 patients, and identify pre-admission prognostic factors of inpatient mortality.…”

Section: Introductionmentioning

confidence: 99%

Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality

Martínez‐López

Mateos

Encinas

et al. 2020

Preprint

View full text Add to dashboard Cite

There is limited information on the characteristics, pre-admission prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with coronavirus disease 2019 (COVID-19). This retrospective case series investigated characteristics and outcomes of 167 MM patients hospitalized with COVID-19 reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in Spain between March 1 and April 30, 2020. Outcomes were compared with a randomly selected contemporary cohort of 167 age-/sex-matched non-cancer patients with COVID-19 admitted at 6 participating hospitals. Common demographic, clinical, laboratory, treatment, and outcome variables were collected; specific disease status and treatment data were collected for MM patients. Among the MM and non-cancer patients, median age was 71 years and 57% of patients were male in each series, and 75% and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate-severe in 77% and 89% of patients and critical in 8% and 4%, respectively. Supplemental oxygen was required by 47% and 55% of MM and non-cancer patients, respectively, and 21%/9% vs 8%/6% required non-invasive/invasive ventilation. Inpatient mortality was 34% and 23% in MM and non-cancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors of inpatient mortality on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality

Martínez‐López

Mateos

Encinas

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…However, for standard-risk patients, only laboratory relapsed without symptoms, postponing the subsequent treatment can be done if possible. 23 The priorities for relapsed or refractory MM patients can be seen in detail in ►Table 3. Similar recommendations were given by IMS in the upfront settings.…”

Section: Approach To Relapse/refractory MM Patientsmentioning

confidence: 99%

Multiple Myeloma Management in COVID-19 Era

Kurniawan

Halim

Sutandyo

2021

ASJO

View full text Add to dashboard Cite

Introduction Coronavirus disease 2019 (COVID-19) has become a world pandemic since early 2020. The complexity of handling multiple myeloma (MM) has increased substantially during this pandemic. The objective of this review is to know the current recommendation to manage MM in the COVID-19 era. Methods Electronic databases, including PubMed central and PubMed, were used to conduct a literature search. It was conducted on May 18, 2020, using the keywords “multiple myeloma” AND “COVID-19” AND “Prevalence OR Impact OR treatment OR prophylactic.” The included articles were review articles, recommendations, case reports or series, or population-based studies (cross-sectional, cohort, case-control, or interventional), and full-text if available. Results A total of 124 articles were identified through the search strategy. The two reviewers screened titles and abstracts of all articles. Most articles were excluded because of ineligible to the criteria. Ultimately, 18 articles were included in the final evaluation. MM patients might have higher risk to become severe COVID-19 if they got infected due to their immunocompromised condition. Due to the pandemic, precise treatment priorities should be made by considering its benefit and the risk of MM progression. For the young, especially healthy patients, the most effective therapy should be offered and tailored to the patient’s goal. Several MM societies have published the recommendation regarding the special stage of MM. Conclusion Myeloma societies in the world have released recommendations related to the management of myeloma patients. However, there is scarce of evidence to do the recommendation.

show abstract

“…Monitoring should be conducted in the closest laboratory, and phone visits may be used for toxicity check. 23,24…”

Section: Approach To Stable Myeloma Patients or In Maintenancementioning

confidence: 99%

Untitled

2021

Asian Journal of Oncology

View full text Add to dashboard Cite

Introduction Coronavirus disease 2019 (COVID-19) has become a world pandemic since early 2020. The complexity of handling multiple myeloma (MM) has increased substantially during this pandemic. The objective of this review is to know the current recommendation to manage MM in the COVID-19 era. Materials and Methods Electronic databases, including PubMed central and PubMed, were used to conduct a literature search. It was conducted on May 18, 2020, using the keywords "multiple myeloma" AND "COVID-19" AND "Prevalence OR Impact OR treatment OR prophylactic." The included articles were review articles, recommendations, case reports or series, or population-based studies (cross-sectional, cohort, case-control, or interventional), and full-text if available. Results A total of 124 articles were identified through the search strategy. The two reviewers screened titles and abstracts of all articles. Most articles were excluded because of ineligible to the criteria. Ultimately, 18 articles were included in the final evaluation. MM patients might have higher risk to become severe COVID-19 if they got infected due to their immunocompromised condition. Due to the pandemic, precise treatment priorities should be made by considering its benefit and the risk of MM progression. For the young, especially healthy patients, the most effective therapy should be offered and tailored to the patient's goal. Several MM societies have published the recommendation regarding the special stage of MM. Conclusion Myeloma societies in the world have released recommendations related to the management of myeloma patients. However, there is scarce of evidence to do the recommendation.

show abstract

Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel – ABHH monoclonal gammopathies committe

Cited by 12 publications

References 21 publications

Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality

Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality

Multiple Myeloma Management in COVID-19 Era

Untitled

Contact Info

Product

Resources

About